Whole-body magnetic resonance imaging in extrathoracic sarcoidosis

European Respiratory Journal

Volumn 43, Issue 6, 2014, Pages 1812-1815

  Hostettler, Katrin E ^a   Bratu, Vlad A ^a   Fischmann, Arne ^a   Tamm, Michael ^a   Studler, Ulrich ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; SOLUBLE INTERLEUKIN 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; BONE LESION; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; EXTRATHORACIC SARCOIDOSIS; FEMALE; FORCED VITAL CAPACITY; HUMAN; INCIDENTAL FINDING; LETTER; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; MENINGIOMA; MUSCLE INJURY; NERVE ROOT LESION; PREVALENCE; PRIORITY JOURNAL; SARCOIDOSIS; SENSITIVITY ANALYSIS; TOTAL LUNG CAPACITY; WHITE MATTER LESION; WHOLE BODY MRI; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SEVERITY OF ILLNESS INDEX; WHOLE BODY IMAGING;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, INTERLEUKIN-2; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84901821047     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00008914     Document Type: Letter

References (15)

1. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75-86. (Pubitemid 29164274)
2. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.
3. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36: 1131-1137.
4. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med 2013; 38: e171-e177.
5. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004; 233: 139-148. (Pubitemid 39280968)
6. Dutoit JC, Vanderkerken MA, Verstraete KL. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent inmultiplemyeloma. Eur J Radiol 2013; 82: 1444-1452.
7. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196.
8. 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012; 53: 1543-1549.
9. Mostard RL, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105: 1917-1924.
10. Otake S, Ishigaki T. Muscular sarcoidosis. Semin Musculoskelet Radiol 2001; 5: 167-170. (Pubitemid 32705949)
11. Hopkins RO, Beck CJ, Burnett DL, et al. Prevalence of white matter hyperintensities in a young healthy population. J Neuroimaging 2006; 16: 243-251. (Pubitemid 44933492)
12. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 123-129.
13. Keijsers RG, van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2013; 41: 743-751.
14. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-399.
15. Hostettler KE, Studler U, Tamm M, et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83: 218-224.